RetourModule 4: Drug-resistant tuberculosis treatment, 2022 update
Module 4: Drug-resistant tuberculosis treatment, 2022 update
Table des matières (version en ligne) :
- Abbreviations
- Acknowledgements
- 1. Introduction
- 2. Commonly used terms and key definitions in DR-TB treatment
- 3. Key considerations in DR-TB treatment
- 4. The 6-month bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) regimen
- 5. The 9-month all-oral regimen
- 6. The longer regimens
- 7. Regimen for rifampicin susceptible and isoniazid resistant TB
- 8. Adjuncts to MDR-TB treatment
-
9. Programmatic implementation of MDR-TB regimens
- 9.1 Policy and operational documents
- 9.2 National MDR-TB expert committee or technical working group
- 9.3 Electronic recording and reporting
- 9.4 Estimates (epidemiological and logistics)
- 9.5 Management of the supply chain and storage conditions for pharmaceuticals
- 9.6 Preparation for the introduction of new treatment regimens
- 10. Treatment outcome definitions
- References
- Annex
VIEW PDF VERSION
Download PPTSuggested citation. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.